MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent.
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy.
MAIA Biotechnology Reports Progress in Cancer Drug Development An announcement from MAIA Biotechnology, Inc. (MAIA) is now available. MAIA Biotechnology, Inc. has announced significant year-to-date achievements…
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent.
MAIA Biotechnology Highlights Clinical Progress and Investor Insights MAIA Biotechnology, Inc. (MAIA) has issued an announcement. MAIA Biotechnology, Inc. recently updated investors with a presentation and summary on …
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024 Biotech Stocks In Focus MAIA Chairman and CEO Vlad Vitoc, M.D. will deliver a presentation featuring up-to-date findings from the Company’s Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small … Continue reading →
MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer.
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention Biotech Stocks In Focus Dr. Vitoc’s presentation is scheduled for Wednesday, June 5 at 11:30 a.m. PDT in Company Presentation Theater 1, located in Hall A of the San Diego Convention Center. Dr. Vitoc and team members will host meetings … Continue reading →
MAIA Biotechnology to Present at the BIO International Convention 2024 MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced its participation in the upcoming BIO International Convention taking place June 3-6, 2024, in San Diego, California. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech Jetzt den vollständigen Artikel lesen
MAIA Biotechnology to Present at the BIO International Convention 2024 CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at the BIO International Convention 2024.